High CD34+ Cell Levels Linked to Better Outcomes in Myeloma
Author Information
Author(s): J Raschle, D Ratschiller, S Mans, B U Mueller, T Pabst
Primary Institution: University Hospital and University of Berne
Hypothesis
Varying levels of mobilised CD34+ cells confer prognostic information in myeloma patients undergoing high-dose chemotherapy.
Conclusion
High levels of mobilised peripheral CD34+ cells are associated with a favourable outcome in myeloma patients undergoing autologous transplantation.
Supporting Evidence
- Patients with more than 100,000 CD34+ cells per ml had better overall survival.
- The study included 158 consecutive myeloma patients.
- High levels of CD34+ cells were an independent marker for better overall survival.
Takeaway
Patients with more CD34+ cells in their blood when collecting stem cells tend to do better after treatment for myeloma.
Methodology
The study measured circulating CD34+ cells in 158 myeloma patients at the time of stem cell collection and compared outcomes based on cell levels.
Potential Biases
Potential biases due to the retrospective nature of the study.
Limitations
The study is retrospective, which may introduce biases.
Participant Demographics
Patients were consecutive myeloma patients undergoing autologous stem cell transplantation.
Statistical Information
P-Value
0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website